Immix Biopharma, Inc.

The momentum for this stock is not very good. Immix Biopharma, Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Immix Biopharma, Inc..

News

Financial Survey: Immix Biopharma (NASDAQ:IMMX) vs. Altimmune (NASDAQ:ALT)

Ticker Report Immix Biopharma (NASDAQ:IMMX - Get Free Report) and Altimmune (NASDAQ:ALT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two...\n more…

Insider Spends US$52k Buying More Shares In Immix Biopharma

Simply Wall St Whilst it may not be a huge deal, we thought it was good to see that the Immix Biopharma, Inc. ( NASDAQ:IMMX...\n more…

Immix Biopharma announces three more sites for NEXICART-2 trial

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

$Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2$

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2

Globe Newswire New Sites Expand Opportunities for Patient Access and Enrollment Clinical Trial Sites Added Include Cleveland Clinic, UC Davis, and Sutter Health Lead site Memorial Sloan Kettering Cancer Center...\n more…

HC Wainwright Weighs in on Immix Biopharma, Inc.'s Q3 2024 Earnings (NASDAQ:IMMX)

Ticker Report Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - HC Wainwright boosted their Q3 2024 earnings per share estimates for Immix Biopharma in a report issued on Monday, August 19th. HC Wainwright...\n more…

Q3 2024 EPS Estimates for Immix Biopharma, Inc. (NASDAQ:IMMX) Lifted by HC Wainwright

Zolmax Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) - Investment analysts at HC Wainwright increased their Q3 2024 earnings per share (EPS) estimates for shares of Immix Biopharma in a note issued to...\n more…